{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018798","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.310771+00:00","generated_at":"2026-06-02T02:06:04.401696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track","bullets":["Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.","R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.","Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.","Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.","Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018798","json":"https://secwatch.observer/filing/0001493152-24-018798.json","markdown":"https://secwatch.observer/filing/0001493152-24-018798.md","text":"https://secwatch.observer/filing/0001493152-24-018798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/0001493152-24-018798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:06:04.401696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7dc7debb7dcf39643edf99853256c424146802a9","claim":"Cocrystal Pharma, Inc. reported financial results for Q1 2024.","evidence_excerpt":"Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224018798/0001493152-24-018798-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}